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Abstract: Adipose tissue (AT) has a modulating role in obesity-induced metabolic complications like
type 2 diabetes mellitus (T2DM) via the production of so-called adipokines such as leptin, adiponectin,
and resistin. The adipokines are believed to influence other tissues and to affect insulin resistance,
liver function, and to increase the risk of T2DM. In this study, we examined the impact of intervention
with the short-chain fatty acid butyrate following a high-fat diet (HFD) on AT function and other
metabolic risk factors associated with obesity and T2DM in mice during mid- and late life. In both
mid- and late adulthood, butyrate reduced HFD-induced adipocyte hypertrophy and elevations in
leptin levels, which were associated with body weight, and cholesterol and triglyceride levels. HFD
feeding stimulated macrophage accumulation primarily in epididymal AT in both mid- and late life
adult mice, which correlated with liver inflammation in late adulthood. In late-adult mice, butyrate
diminished increased insulin levels, which were related to adipocyte size and macrophage content
in epididymal AT. These results suggest that dietary butyrate supplementation is able to counteract
HFD-induced detrimental changes in AT function and metabolic outcomes in late life. These changes
underlie the obesity-induced elevated risk of T2DM, and therefore it is suggested that butyrate has
potential to attenuate risk factors associated with obesity and T2DM.
Keywords: obesity; T2DM; high-fat diet; butyrate; adipose tissue; macrophages; adipokines
1. Introduction
In line with the rise of type 2 diabetes mellitus (T2DM) the global prevalence of obesity has
more than doubled since 1980 [1]. Moreover, obesity is a major risk factor for T2DM, accounting
for 80–85% of the overall risk [2]. Weight or fat loss has the strongest effect on reducing the risk of
developing T2DM [3]. It has been suggested that the relationship between obesity and T2DM exists
already at a young age [4–6]. In addition, obesity is suggested to exaggerate aging processes [7],
and aging is associated with impaired insulin signaling [8], which causes an increase in blood glucose
levels. Over time, high blood glucose concentrations combined with high blood pressure and high
cholesterol levels affect vascular function, and may evolve into cardiovascular disease, kidney failure,
and subsequent cognitive deficits [9,10].
Accumulating evidence suggests that adipose tissue dysfunction—with adipocyte hypertrophy
as a first manifestation—may play a role in the development of obesity-induced metabolic conditions
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that increase the risk for T2DM [11]. Adipocyte hypertrophy results in an elevated recruitment of
macrophages surrounding dead or dying adipocytes, which is referred to as crown-like structures
(CLS)—an important hallmark of adipose tissue dysfunction— [12]. Macrophages are believed to be
major sources of inflammatory cytokines with detrimental effects on insulin signaling in obesity [13].
In addition, adipocyte hypertrophy may lead to the altered production and secretion of adipokines like
leptin, resistin, serum amyloid A (SAA), and adiponectin [14–16]. These adipokines play important
roles in insulin signaling and the development of a chronic low-grade inflammatory state, which is
characteristic for obesity. Overall, amelioration of these obesity-induced and adipose tissue-related
changes may provide an important approach to attenuate the risk of developing T2DM.
There is a growing interest in short-chain fatty acids—such as butyrate—as dietary intervention
for obesity and related metabolic diseases [17,18]. Butyrate is one of the fatty acids produced during
bacterial fermentation in the distal gut of nondigestible carbohydrates like dietary fiber and resistant
starch. Both intake of butyrate and dietary fibers have shown positive effects on body weight and
insulin sensitivity [17,19–22]. In addition, butyrate has anti-inflammatory properties and affects
lipogenesis [17]. A decreased concentration of butyrate-producing bacteria has been observed both
in patients with obesity [23] and T2DM [24]. Butyrate may therefore play an essential role in the
maintenance of an optimal metabolic state.
It is acknowledged that obesity may differentially affect various organs and tissues, like the
brain and cardiovascular system, during midlife as opposed to late life [18,25–27]. Recently, we
demonstrated that butyrate is able to restore high-fat diet (HFD)-induced neuroinflammation and
changes in brain function in low-density-lipoprotein receptor knockout (LDLr-/-).Leiden mice in
mid-adulthood [18]. In addition, mid-adult mice seem to be more susceptible to the development of
HFD-induced cardiovascular damage as compared to late-adult mice [18]. However, it has not been
elucidated whether diet-induced obesity affects adipose tissue function and its metabolic outcomes
differentially during mid- and late adulthood. As follow-up of the previous published study [18],
we investigated in the current study the effects of a therapeutic butyrate intervention on adipose tissue
function and adipokine levels in the context of manifested HFD-induced obesity in both mid- and
late-adult LDLr-/-.Leiden mice.
2. Materials and Methods
2.1. Animals and Diets
The adipose tissues and plasma samples analyzed in this experiment originate from a previously
described study [18]. LDLr-/-.Leiden mice were selected because of their high sensitivity to developing
HFD-induced obesity and subsequent complications like vascular damage and fatty liver [28–30].
Briefly, male LDLr-/-.Leiden mice (TNO Metabolic Health Research, Leiden, The Netherlands) were
housed in individually ventilated cages in a conventional animal room situated in the preclinical
imaging center (PRIME) at the central animal laboratory, Radboudumc Nijmegen, the Netherlands.
A maximum of five mice were housed per cage with ad libitum access to acidified tap water and
food (temperature 21 ◦C; relative humidity 50–60%; light-dark cycle 7 a.m.–7 p.m.). The experiments
were approved by an independent ethical committee on animal care and experimentation (Zeist,
The Netherlands), approval project number DEC3682 [18] and carried out in accordance to the
ARRIVE guidelines [31].
The intervention regimen of the study [18] is schematically presented in Figure 1. A total group of
n = 60 LDLr-/-.Leiden mice were divided into a mid- and late-adult cohort (n = 30 each). Both cohorts
consisted of three diet groups. For the cohort representing mid-adulthood, the first group received a
chow diet from birth until the end of the study (Chow). The second group switched to a HFD at three
months of age (HFD). The third group switched to a HFD when three months old (m.o.) as well, but
this HFD was subsequently enriched with 5% w/w butyrate from seven months of age until the end of
the study (HDFB) (Figure 1a). The cohort representing late adulthood was subdivided in the same
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manner, but mice were switched to HFD at six months of age and butyrate intervention started at 10
months of age (Figure 1b).
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Figure 1. Schematic overview of the study design. (a) Mid-adulthood, exposure of the high-fat died 
HFD started at 3 m.o. in the HFD and HFDB groups. At 7 months of age, the butyrate intervention 
(HFD supplemented with 5% w/w butyrate) started in the HFDB group; (b) Late adulthood, exposure 
to the HFD started at 6 months of age in the HFD and HFDB groups, and a butyrate intervention 
initiated at 10 months of age in the HFDB group. Body weight (individual) and food intake (cage 
level) were monitored weekly. Blood samples were taken after five hours of fasting. At 9 m.o. and 12 
m.o., mice were sacrificed and both liver and adipose tissues were harvested. These tissues were 
subsequently processed for immunohistochemical staining. B = blood sample collection; HFD = 
high-fat diet; HFDB = high fat diet enriched with butyrate; m.o. = months old.  
2.2. Plasma Analyses 
Blood was collected after five hours of fasting (8 a.m. to 1 p.m.). Plasma cholesterol, triglyceride 
and insulin levels were measured using standardized ELISA kits as previously described [18]. 
Moreover, ELISA kits (Quantikine, R&D systems, Inc., Minneapolis, MN, USA) were used to define 
plasma leptin (DY498), adiponectin (DY1119), resistin (DY1069) and interleukin-6 (IL-6; M6000B) 
levels. SAA plasma levels were determined by an ELISA kit as well (KMA0021, Invitrogen, 
Carlsbad, CA, USA).  
2.3. (Immuno)histochemistry 
Mice were sacrificed by transcardial perfusion with 0.1 M phosphate buffered saline (PBS) after 
being anesthetized with isoflurane (3.5%, Nicholas Primal (I) limited, London, UK), as described in 
Arnoldussen et al. [18]. Directly thereafter, the liver and two different adipose tissue depots were 
harvested and post-fixed in 4% paraformaldehyde for 24 h. Fat depots seem to be differentially 
active and affected by a HFD and, therefore, we dissected in addition subcutaneous (inguinal) and 
visceral (epididymal) adipose tissue depots [32,33]. Liver outcomes used for correlation analyses 
were obtained from a previous experiment [18].  
Both epididymal and inguinal adipose tissues were processed for immunohistochemistry on 5 
μm paraffin embedded sections. Briefly, paraffin sections were first deparaffinized in xylene and 
rehydrated in a series of ethanol followed by endogenous peroxidase blocking with 0.3% H2O2 in 0.1 
M PBS. Antigen retrieval was achieved by treating the tissue in hot 0.05 M sodiumcitrate with a 
constant temperature of 85 °C. After pre-incubation with 0.1% bovine serum albumin in 0.1 M PBS 
(PBS-B), the tissue was incubated overnight at room temperature with primary macrophage 
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rehydrated in a s ries of thanol followed by endogen u peroxidase blocking with 0.3% H2O2 in
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(PBS-B), the tissue was incubated overnight at room temperature with primary macrophage (MAC-3)
antibodies (1:100; eBioscience, 14-1072) [34]. Next, sections were incubated with secondary donkey
anti-rat IgG antibodies (1:200; Jackson ImmunoResearch) in 0.1 M PBS-B at room temperature. Staining
was visualized using the ABC method with a Vectastain kit (Vector Laboratories, Burlingame, CA,
USA) and diaminobenzidine imidazole solution as chromogen. Finally, sections were dehydrated in a
series of ethanol, cleared in xylene, and mounted.
Two entire sections per animal were visualized using a VisionTek live digital microscope (Sakura
Finetek, Torrance, CA, USA) at a 10× magnification. Sampling of these sections was carried out with
Adobe Illustrator CC 2016 (Adobe, San Jose, CA, USA) using a template with three randomly placed
artboards (592.7 × 886.2 mm). Adipocyte cell size (µm2) and the number of CLS were determined in a
total of six samples—three samples per section—per animal. Analyses to determine these measures
were performed using CellProfiler [35] version 2.3.0 together with Ilastik version 0.5 [36] for pixel
classification. Separate pipelines and classifiers for epididymal and inguinal adipose tissue analyses
were used. In order to verify the reliability of these relatively novel analyses, we included an established
analysis to determine adipocyte size using ImageJ software as previously described [37]. CLS were
determined based on intensity of the cell edge, and total numbers of CLS per animal were calculated
per 1000 adipocytes.
2.4. Statistical Analyses
A random and blinded selection procedure was maintained throughout the study. Group means
were compared using univariate analysis of variance (ANOVA) with Bonferroni correction for multiple
testing with a statistical program, SPSS 24 (IBM SPSS Statistics 24, IBM Corporation, Armonk, NY,
USA). Parameter correlation tests were performed using Pearson correlations. Nonparametric tests
were used when assumptions of normality and homogeneity of variance were not met. p-values lower
than 0.05 were considered significant. Data are presented as mean ± SEM.
3. Results
3.1. Adipocyte Size
Adipocyte size—measured as area (µm2)—of both epididymal and inguinal adipose tissue depots
were determined to assess morphological adaptations. A HFD increased the average epididymal
adipocyte size in both mid- and late-adult mice (mid: p < 0.001; F(1,18) = 26.05, late: p < 0.02;
F(1,19) = 7.01) (Figure 2a). Butyrate intervention significantly reduced adipocyte size in both age
cohorts (mid: p = 0.001; F(1,18) = 14.95, late: p < 0.02; F(1,18) = 7.14).
Similarly, inguinal adipocyte size was increased by HFD in both mid- and late adulthood
(p = 0.001; mid: F(1,18) = 20.49, late: F(1,19) = 14.25) (Figure 2b). After HFD exposure, inguinal
adipocyte size was reduced due to butyrate intervention in mid-adult mice (p < 0.001; F(1,18) = 25.69),
but not in late-adult mice. Mean inguinal adipocyte size was significantly larger in late adult as
compared to mid-adult high fat diet enriched with butyrate (HFDB) mice (p < 0.01; F(1,18) = 11.28).
In addition, we compared the number of adipocytes as an additional indication of adipose tissue
function. Our analysis indicated that the epididymal adipose tissue contained a lower number of
adipocytes than inguinal adipose tissue. The mean adipocyte number in epididymal adipose tissue
was higher in mid-adult Chow mice as compared to HFD mice (Table 1). Butyrate intervention
increased epididymal adipocyte number solely in mid-adulthood. In both age cohorts, inguinal
adipocyte numbers were significantly higher in Chow mice as opposed to HFD mice (Table 1). Only in
mid-adulthood did butyrate intervention increase the inguinal adipocyte numbers.
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(mid: p < 0.01; R = 0.55, late: p < 0.001; R = 0.64). Solely in late adulthood, epididymal adipocyte size 
correlated positively with plasma insulin levels (p < 0.01; Table 3).  
Moreover, body weight, cholesterol and triglyceride levels revealed significant and positive 
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Figure 2. Adipose tissue cell sizes and macrophage infiltration. Mean adipocyte sizes in epididymal
(a) and inguinal (b) adipose tissue depots in both mid- (9 m.o.) and late- (12 m.o.) adult mice.
(c,d) Mean number of crown-like structures (CLS) in epididymal (c) and inguinal (d) adipose tissue.
(e) Representative photomicrographs of epididymal adipose tissue stained with antibodies against
macrophages (MAC-3) in late-adult mice. In addition, a magnification (40×) of a CLS is represented.
These examples are comparable to those observed in mid-adulthood. Data are presented as mean ±
standard error of mean (SEM). * p < 0.05; ** p < 0.01; *** p ≤ 0.001.
In mid- and late adulthood, both epididymal and inguinal adipocyte size were positively
associated with body weight, and cholesterol and triglyceride plasma levels (Tables 2 and 3). In
addition, only inguinal adipocyte size was positively correlated with inguinal adipose tissue weight
(mid: p < 0.01; R = 0.55, late: p < 0.001; R = 0.64). Solely in late adulthood, epididymal adipocyte size
correlated positively with plasma insulin levels (p < 0.01; Table 3).
Moreover, body weight, cholesterol and triglyceride levels revealed significant and positive inter
correlations (Tables 2 and 3). Finally, insulin levels correlated positively with these outcomes in
late-adult mice (Table 3).
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Table 1. Adipocyte numbers. Represented are the combined mean numbers of two slides.
Adipocyte Numbers Per 106 µm2 (Mean± SEM)
Epididymal
Chow vs. HFD
mid 468 ± 34 vs. 376 ± 31 0.05 < p < 0.08 F(1,18) = 3.95
late 452 ± 40 vs. 410 ± 21 p = 0.02 F(1,18) = 6.54
HFD vs. HFDB
mid 376 ± 31 vs. 496 ± 35 ns
late 410 ± 21 vs. 481 ± 47 ns
Inguinal
Chow vs. HFD
mid 665 ± 59 vs. 449 ± 16 p < 0.01 F(1,18) = 12.61
late 659 ± 44 vs. 474 ± 41 p < 0.01 F(1,19) = 9.54
HFD vs. HFDB
mid 449 ± 16 vs. 522 ± 15 p < 0.01 F(1,18) = 11.27
late 474 ± 41 vs. 446 ± 18 ns
ns = not significant.
Table 2. Correlation coefficients among mid-adult mice.
BW Chol Trigl eAS iAS eCLS iCLS Leptin SAA
BW x
Chol 0.80 R + x
Trigl 0.58 R + 0.69 R + x
eAS 0.53 R + 0.64 R + 0.57 R + x
iAS 0.55 R + 0.57 R + 0.37 R + NE x
eCLS 0.53 τb + 0.49 τb + 0.15 τb + 0.24 τb + NE x
iCLS 0.31 τb + 0.29 τb + 0.10 τb + NE 0.37 τb + NE x
Leptin 0.78 R + 0.87 R + 0.62 R + 0.76 R + 0.67 R + 0.52 τb + 0.37 τb + x
SAA 0.56 τb + 0.50 τb + 0.13 τb + 0.17 τb + 0.24 τb + 0.69 τb + 0.28 τb + NE x
Either the Pearson’s (R) or Kendall’s tau (τb) test was used. Not significant. + = positive correlation; Adi =
adiponectin; BW = body weight; Chol = cholesterol; eAS = epididymal adipocyte size; eCLS = epididymal CLS; iAS
= inguinal adipocyte size; iCLS = inguinal CLS; LI = liver inflammation; NE = not estimated; SAA = serum amyloid
A; Trigl = triglycerides.
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Table 3. Correlation coefficients among late-adult mice.
BW Insulin Chol Trigl eAS iAS eCLS iCLS LI Leptin Adi SAA
BW x
Insulin 0.66 R + x
Chol 0.87 R + 0.66 R + x
Trigl 0.79 R + 0.77 R + 0.81 R + x
eAS 0.52 R + 0.49 R + 0.57 R + 0.53 R + x
iAS 0.47 R + 0.31 R + 0.54 R + 0.50 R + NE x
eCLS 0.43 τb + 0.30 τb + 0.55 τb + 0.34 τb + 0.23 τb + NE x
iCLS 0.45 τb + 0.21 τb + 0.38 τb + 0.33 τb + NE 0.37 τb + NE x
LI 0.41 τb + 0.33 τb + 0.45 τb + 0.30 τb + 0.15 τb + 0.22 τb + 0.57 τb + 0.21 τb + x
Leptin 0.88 R + 0.69 R + 0.91 R + 0.87 R + 0.65 R + 0.64 R + 0.49 τb + 0.41 τb + 0.46 τb + x
Adi 0.56 R − 0.48 R − 0.68 R − 0.47 R − 0.25 R − 0.25 R − 0.19 τb − 0.30 τb − 0.28 τb − NE x
SAA 0.42 τb + 0.29 τb + 0.57 τb + 0.46 τb + 0.19 τb + 0.53 τb + 0.58 τb + 0.30 τb + 0.44 τb + NE NE x
Either the Pearson’s (R) or Kendall’s tau (τb) test was used. Not significant. + = positive correlation; − = negative correlation; Adi = adiponectin; BW = Body weight; Chol = cholesterol;
eAS = epididymal adipocyte size; eCLS = epididymal CLS; iAS = inguinal adipocyte size; iCLS = inguinal CLS; LI = liver inflammation; NE = not estimated; SAA = serum amyloid A;
Trigl = triglycerides.
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3.2. Inflammation in Adipose Tissue and Liver
To assess the degree of inflammation in adipose tissue, the number of adipocytes infiltrated by
macrophages—known as crown-like structures (CLS)—has been determined. Both mid- and late-adult
mice on HFD showed higher numbers of CLS in epididymal adipose tissue as opposed to Chow-fed
mice (Kruskal Wallis: p < 0.001; mid: χ2(1) = 13.50, late: χ2(1) = 13.02) (Figure 2c). No effects of butyrate
on CLS number in epididymal adipose tissue were observed. In inguinal adipose tissue, the number
of CLS was increased after HFD exposure in both mid- (Kruskal-Wallis: p < 0.01; χ2(1) = 7.30) and
late- (Kruskal-Wallis: p < 0.02; χ2(1) = 6.16) adult mice (Figure 2d). No significant differences in the
number of CLS in inguinal adipose tissue were observed between HFD and HFDB mice (Figure 2d).
As scales differ between Figure 2c,d, caution should be taken when interpreting these results. In
Figure 2e, examples of epididymal adipose tissue stained for macrophages are shown.
In late adulthood, the number of CLS in epididymal adipose tissue correlated significantly with
body weight (p = 0.001), and plasma triglyceride (p < 0.02), cholesterol (p < 0.001) and insulin (p < 0.05)
levels (Table 3). In mid-adulthood, epididymal adipose tissue CLS content showed only significant
correlations with body weight (p < 0.001) and plasma cholesterol levels (p < 0.001) (Table 2).
In addition to CLS in adipose tissue, data including inflammatory aggregates were used [18] to
examine potential relationships to inflammation in the liver, which is another crucial organ regulating
insulin sensitivity. Liver inflammation was increased after HFD exposure only in late-adult mice [18].
No significant changes were observed after butyrate intervention. In this age cohort, the number of
inflammatory aggregates in the liver was positively correlated with the number of CLS in epididymal
adipose tissue (p < 0.001) (Table 3).
3.3. Adipokine Plasma Levels
Adipokine plasma levels were determined at either nine or 12 months of age. HFD exposure
strongly increased leptin plasma levels in both age cohorts (p < 0.001; mid: F(1,18) = 50.10, late:
F(1,19) = 44.87) (Figure 3a). Late-adult HFD-fed mice showed higher leptin levels as compared to
mid-adult mice fed a HFD (p < 0.02; F(1,19) = 7.71). Subsequent butyrate intervention resulted in
reduced plasma leptin levels, almost reaching control levels in Chow mice (p < 0.001; mid: F(1,18)
= 26.49, late: F(1,18) = 32.88). HFD did not affect plasma resistin levels (Figure 3b). Adiponectin
plasma levels were reduced after HFD exposure in late-adult mice (p < 0.001; F(1,19) = 17.57) and were
moderately increased after butyrate intervention (p = 0.053; F(1,18) = 4.29) (Figure 3c). An age effect
was observed in both Chow and HFD animals (p < 0.05; F(1,18) = 4.60 and F(1,19) = 4.55, respectively).
Serum amyloid A (SAA) plasma levels were increased in mice fed a HFD when compared to Chow-fed
mice in both age cohorts (Kruskal-Wallis: p ≤ 0.001; mid: χ2(1) = 10.14, late: χ2(1) = 14.46) (Figure 3d).
Plasma levels of interleukin-6 (IL-6) were below detectable levels in all animals in the absence of
abnormal positive and negative controls.
In both mid- and late adulthood, plasma leptin levels were positively correlated with body weight
(p < 0.001), both epididymal and inguinal adipocyte size (p < 0.001), and epididymal CLS content
(p < 0.001) (Tables 2 and 3). Solely in late-adult mice, plasma leptin levels positively correlated with
insulin levels (p < 0.001) and liver inflammation (p = 0.001) (Table 3). Only in late adulthood plasma
adiponectin levels showed a negative correlation with body weight (p < 0.01), insulin plasma levels (p
< 0.02), and liver inflammation (p < 0.05) (Table 3).
Plasma SAA levels were positively correlated with body weight (mid: p < 0.001, late: p < 0.01) and
the number of CLS in epididymal adipose tissue (p < 0.001) in both mid- and late adulthood (Tables 2
and 3). Whereas, SAA plasma levels were positively correlated with insulin levels (p < 0.05), inguinal
adipocyte size (p < 0.001), and liver inflammation (p < 0.01) only in late adulthood (Table 3).
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Figure 3. Adipokine plasma levels. Mean plasma levels of leptin (a), resistin (b), adiponectin (c),
and serum amyloid A (SAA) (d) are represented in both mid- (9 m.o.) and late- (12 m.o.) adult mice as
mean ± SEM. *** p ≤ 0.001; # p = 0.053.
4. iscussion
This study describes the detri ental effects of a six- onth FD exposure in id-adult and
late-adult ice, and exa ined potential health effects of butyrate ad inistered during the last t o
onths of HFD feeding. In this study, HFD exposure caused adipocyte hypertrophy and inflammation,
as well as an increase in the plasma levels of proinflammatory adipokines (leptin, SAA) in mid- and
late life. Butyrate attenuated HFD-evoked effects, though the effects of butyrate varied in mice that
were exposed to HFD in mid-life as compared to late life.
In our study, F treat ent increased body eight and adiposity, and subsequent butyrate
intervention diminished these changes in the LDLr-/-.Leiden mice [18]. Moreover, these changes were
observed without significant differences in calorie intake, suggesting that energy intake was similar
between the dietary interventions. Other rodent research has shown that a HFD increases body weight
and adiposity [38–40], and similar effects of butyrate have been reported in obese mice [38,41]. The
LDLr-/-.Leiden mouse model was chosen for this study because of its high sensitivity to develop
vascular complications and obesity when fed a HFD even with modest fat content. We found that 12
m.o. LDLr-/-.Leiden mice on standard Chow show a disposition towards pronounced weight gain and
are approximately 32% heavier than Chow-fed male C57BL/6 mice of the same age [42], supporting
the obesity-prone condition of the model chosen. It is unclear why these mice are susceptible to obesity
development, and comparative molecular analysis to C57BL/6 mice have not been ade. In our
experi ental design, a control group of wild-type mice was not included due to restrictions in mice per
experiment and time. Therefore, a generalization of the results cannot be made, the more so because
the interaction between the LDLr-/- genotype and HFD are still not fully understood. A detailed
comparison with wild-type ice and other obesity models would be required to elucidate the role of
the LDLr in obesity.
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In a previous study, insulin levels were significantly increased in late-adult mice after HFD
feeding, whereas no changes in glucose levels were observed [18]. Plasma insulin levels are extremely
high due to the experimental conditions employed in this disease model (>20 ng/mL) and much
higher than in wild-type mice fed the same diet (<5 ng/mL) [18,30], indicating insulin resistance
but no overt T2DM because glucose levels are not elevated and seem to be controlled. Interestingly,
butyrate supplementation restored insulin levels to values found in Chow-fed mice, suggesting an
improvement in insulin signaling [18]. Previous research described similar effects of butyrate on insulin
levels and sensitivity in HFD-fed mice [38,43]. It is not clear whether this effect of butyrate is mediated
by improvement of insulin signaling in liver, in peripheral organs, or both. It is possible that both
organs are involved, given the time frame in which insulin resistance develops under the conditions
employed. For instance, a time resolved clamp study using C57BL/6 mice that were treated with the
same HFD as used in the current study showed that the adipose tissue develops insulin resistance
after about six to 12 weeks of HFD feeding [44]. Second, the development of insulin resistance in the
liver requires longer periods of HFD feeding (about 24 weeks), i.e., a period that is comparable to the
duration of HFD exposure herein [44].
Even in the absence of obesity, metabolic dysfunction in adipose tissue induced by adipocyte
hypertrophy has consistently been related to insulin resistance and may serve as a predictor for
T2DM [45,46]. We observed increased adipocyte size in both epididymal and inguinal adipose tissue
depots after HFD feeding. Adipocyte hypertrophy was reduced by butyrate with the exception of
inguinal adipose tissue in late-adult mice. Epididymal adipocyte sizes were associated with insulin
levels in late adulthood suggesting that epididymal, as opposed to inguinal, adipose tissue may be
important in mediating the effects on insulin. Previous studies have demonstrated the significant
role of visceral fat in mediating insulin sensitivity in rats [47,48], which may be attributed to the
higher degree of metabolic activity of visceral fat as opposed to subcutaneous fat [16,49,50]. The
beneficial effects of butyrate on adipocyte size in epididymal adipose tissue have been demonstrated
before [51]. Although our knowledge about the exact mechanisms is incomplete, it is likely that
butyrate may reverse adipocyte hypertrophy by promoting fatty acid oxidation in adipose tissue [38].
In particular, butyrate may induce a shift from lipid synthesis to utilization resulting in decreased
fat storage in white adipose tissue [43]. Our data confirm this hypothesis as adipocyte sizes were
significantly associated with both cholesterol and triglyceride levels. Dyslipidemia is a regularly
observed condition in T2DM patients [52]. HFD-induced elevations in cholesterol and triglycerides
were diminished by butyrate in LDLr-/-.Leiden mice [18], suggesting a mitigation of hyperlipidemia
that is not related to enhanced clearance, suggesting effects on very-low-density lipoprotein (VLDL)
production. For instance, butyrate may affect hyperlipidemia as it can induce a switch from lipid
synthesis to utilization [53]. Unfortunately, our study is limited with respect to functional analyses such
as glucose transport, insulin signaling, lipogenesis, and adipogenesis in adipose tissue. Therefore, it
would be valuable to investigate these aspects in future studies. The effects of butyrate supplementation
on key regulators of adipogenesis in mid-adult versus late-adult mice may provide insight into the
pathways by which butyrate may modulate adiposity. It has been shown that butyrate may reduce
body weight and improve insulin sensitivity via the modulation of peroxisome proliferator-activated
receptor-γ (PPAR-γ) [43], which is a key regulator of adipogenesis [54]. Consistent with this, we
recently showed that specific activation of PPAR-γ in adipose tissue attenuates CLS development and,
related to this, the development of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis [55].
Anti-inflammatory effects in adipose tissue may attenuate the release of inflammatory mediators and
may also affect the development of diseases in other organs such as the liver [56,57]. A notion which is
further supported by the coordinated and interactive expression of inflammatory genes in adipose
tissue and liver during metabolic overload [58].
It is well established that a correlative and causative relation exists between chronic inflammation
and both insulin resistance and T2DM in humans and rodents [13,59]. More specifically, a reduction of
macrophage infiltration in adipose tissue can improve insulin sensitivity in diet-induced obese mice
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by reducing the expression of inflammatory cytokines in adipose tissue [11]. As shown in the present
study, HFD feeding results in increased macrophage infiltration mainly in epididymal adipose tissue
associated with body weight and insulin levels. Epididymal adipose tissue was characterized by an
abundance of CLS, whereas CLS were almost absent in inguinal adipose tissue, which is consistent
with previous studies investigating adipose tissue inflammation of various adipose tissue depots in
the context of their expandability and maximal storage capacity [30,57]. It is possible that visceral
fat may excrete higher amounts of inflammatory proteins and fatty acids affecting insulin signaling,
and that macrophages play an important role in this [56,60]. CLS formation in epididymal adipose
tissue was not affected by butyrate supplementation in mid-adult mice, whereas a mean reduction of
almost 33% was observed in late-adult mice. Consistent with the inflammatory cross-talk between
epidydimal adipose tissue and liver, medial lobular inflammation was not affected in mid-adult mice,
whereas the number of inflammatory aggregates in the liver was reduced by 44% after dietary butyrate
intervention in late-adult mice [18]. Furthermore, liver inflammation in late-adult mice, indicated
by inflammatory aggregates in the medial lobe [18], correlated significantly with the number of CLS
in epididymal adipose tissue in this study. It is not known via which pathways butyrate can affect
inflammation, and future studies may examine the expression of inflammatory mediators at tissue
level, in both adipose tissue and the liver. In addition, mechanistic studies examining the expression of
transcription factors, such as nuclear factor κB, support the notion that the activation of inflammatory
processes in adipose tissue and liver are necessary.
Both the increase in pro-inflammatory and the reduction in anti-inflammatory adipokine secretion
by adipose tissue can contribute to systemic and tissue-specific inflammation. In this study, HFD
exposure results in increased levels of leptin and serum amyloid A (SAA). These findings are
accompanied by a reduction in adiponectin in late adulthood, whereas it remains unclear why
adiponectin was not affected by HFD or butyrate treatment in mid-adult mice. An exaggerated
metabolic load in adipocytes and inflammatory state may underlie the effects of a HFD on leptin,
adiponectin, and SAA levels [16]. Both leptin and SAA are suggested to be pro-inflammatory
adipokines, whereas adiponectin has anti-inflammatory properties [61]. Leptin contributes to the
inflammatory state in obesity by modulating TNF-α and activating macrophages [62], and butyrate
reduced leptin levels in mid-adult and late-adult mice. Leptin can also affect insulin sensitivity by
modulating pancreatic β-cells [60]. It thereby contributes to the observed reduction in plasma insulin
by butyrate in late-adult mice the more, because butyrate reduced leptin levels nearly to those of
Chow-fed mice. Our finding that leptin levels were significantly related to insulin levels in late-adult
mice further supports this notion. Although current evidence for the role of SAA in insulin signaling is
contradictory [63–65], SAA levels have been correlated with insulin resistance and T2DM [66], which
may be related to the pro-inflammatory properties of SAA [14]. Interestingly, adiponectin plasma
levels were only affected by HFD feeding in late-adult mice. It is possible that the circulating SAA is
mainly released from adipose tissue and that butyrate reduced CLS only in adipose tissue of late-adult
mice. Low adiponectin levels may add to an impaired insulin signaling via polarization towards
M1 macrophages in adipose tissue [67]. Butyrate intervention reduced changes in both leptin and
adiponectin levels, which may in part be attributed to its effect on adipocyte size and its differential
effects on CLS, i.e., adipose tissue inflammation, in mid-and late-adult mice.
5. Conclusions
This study provides evidence that dietary supplementation with butyrate constitutes a strategy
to counteract features of HFD-induced adipose tissue dysfunction and accompanying metabolic
disturbances. These metabolic adaptations often affect insulin signaling and may therefore indicate
an increased risk of developing T2DM. Late-adult mice are particularly sensitive to HFD-evoked
metabolic risk factors and adaptations. The findings of the current study provide novel insights about
the attenuating effects of butyrate on adipose tissue dysfunction and inflammation. Overall, dietary
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interventions with butyrate may constitute means to ameliorate the risk of developing metabolic
disorders such as T2DM in people with obesity.
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